1

2 Title: Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern 3 with under-reporting of prevalence and deaths

- 4
- 5 Authors: Mahan Ghafari,¹* Bardia Hejazi,² Arman Karshenas,³ Stefan Dascalu,^{1,4} Alireza
- 6 Kadvidar,⁵ Mohammad A. Khosravi,⁶ Maryam Abbasalipour,⁶ Majid Heydari,⁷ Sirous Zeinali,^{6,8}
- 7 Luca Ferretti,⁹ Alice Ledda,¹⁰ Aris Katzourakis¹*

8 Affiliations:

- ⁹ ¹ Department of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford,
- 10 Oxford, UK.
- ¹¹ ² Department of Physics, Wesleyan University, Middletown, Connecticut, USA.
- ³ Department of Engineering, University of Oxford, Oxford, UK.
- ⁴ Avian Influenza Virus, The Pirbright Institute, Woking, UK.
- ¹⁴ ⁵ Center for Statistical and Operational Research, Statsminutes Company, Tehran, Iran.
- ⁶ Kawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.
- ⁷ Editorial board, Donya-e-Eqtesad Daily newspaper, Tehran, Iran.
- ¹⁷ ⁸ Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran,
- 18 Tehran, Iran.
- ⁹ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of
- 20 Oxford, Oxford, UK.
- ¹⁰ Department of Infectious Disease Epidemiology, Imperial College London, UK.
- 22 * Corresponding author.
- 23 Email: <u>mahan.ghafari@zoo.ox.ac.uk</u> (MG); <u>aris.katzourakis@zoo.ox.ac.uk</u> (AK)

One Sentence Summary: We use epidemiological and genetic data to investigate the origins of the SARS-CoV-2 outbreak in Iran and assess the degree of under-reporting in prevalence and

deaths.

27 Abstract:

Many countries with an early outbreak of SARS-CoV-2 struggled to gauge the size and start date 28 of the epidemic mainly due to limited testing capacities and a large proportion of undetected 29 asymptomatic and mild infections. Iran was among the first countries with a major outbreak 30 outside China. Using all genomic sequences collected from patients with a travel link to Iran, we 31 estimate that the epidemic started on 21/01/2020 (95% HPD: 05/12/2019 - 14/02/2020) with a 32 doubling time of 3 days (95% HPD: 1.68 - 16.27). We also show, using air travel data from 33 confirmed exported cases, that from late February to early March the number of active cases 34 across the country were more than a hundred times higher than the reported cases at the time. A 35 detailed province-level analysis of all-cause mortality shows 20,718 (CI 95%: 18,859 - 22,576) 36 excess deaths during winter and spring 2020 compared to previous years, almost twice the 37 number of reported COVID-19-related deaths at the time. Correcting for under-reporting of 38

39 prevalence and deaths, we use an SEIR model to reconstruct the outbreak dynamics in Iran. Our 40 model forecasted the second epidemic peak and suggests that by 14/07/2020 a total of 9M (CI 41 95%: 118K – 44M) have recovered from the disease across the country. These findings have 42 profound implications for assessing the stage of the epidemic in Iran and shed light on the 43 dynamics of SARS-CoV-2 transmissions in Iran and central Asia despite significant levels of 44 under-reporting.

45 [Main Text:]

46 Introduction

With significant levels of mortality and morbidity, the ongoing pandemic of Coronavirus Disease 47 2019 (COVID-19) continues to have a major impact on many countries around the world [1]. 48 First reported cases of COVID-19 in Iran were of two infected individuals in the province of Qom 49 on 19 February. In only a few days, reported cases grew rapidly in almost a dozen provinces (see 50 51 Movie S1 and Figure 1a) which raised concerns that the virus had already been widespread by the time the first two cases were detected in Qom. By 28 February, WHO reported nearly 100 52 53 confirmed exported cases of COVID-19 from Iran to several countries [2] while, at the time, the Ministry of Health and Medical Education (MoHME) reported a total of 388 confirmed cases 54 55 across the country [3]. Some early reports suggested that the first two confirmed cases in Qom, one of the thirty-one provinces of Iran, could have been infected by a merchant who had 56 reportedly travelled from China [4]. However, with COVID-19, identifying the so-called 'patient 57 zero' is problematic due to high rates of asymptomatic and pauci-symptomatic infections [5]. 58 59 Indeed, some preliminary analysis by the COG-UK consortium shows that there have likely been more than one thousand unique introductions of the virus into the UK, possibly many of which 60 61 are from individuals who are asymptomatic or show mild symptoms [6]. Therefore, the most likely route of virus spread from China to Iran, and indeed many other countries, was via 62 asymptomatic travelers. Infected individuals typically show no symptoms for about 5 days [7-9] 63 or sometimes no symptoms at all [10-12], while silently spreading the virus [14]. Using aggregate 64 data from the influenza surveillance networks has been proposed as one of the ways to detect 65 early arrival of SARS-CoV-2 into a country [13]. However, a major flu outbreak in Iran which 66 67 reportedly stretched from November 2019 to early January 2020 may have conflicted with the early diagnosis of COVID-19 patient across the country, thereby hindering control and diagnosis 68 efforts [15,16]. 69

During the early days of the epidemic, Pasteur Institute of Iran (PI) was the primary source of 70 testing suspect COVID-19 cases and had enough resources to perform only a few hundred RT-71 72 PCR tests per day. By mid-March, WHO and the Chinese Government delivered several shipments of emergency medical supplies along with more than 200,000 additional test kits which 73 helped with the diagnosis of more hospitalised patients [17]. Nevertheless, some of the 74 75 preliminary analysis showed that Iran was only reporting less than 10% of its symptomatic cases during its first peak in late March [18,19]. From early April, as the country ramped up its testing 76 capacity, MoHME started to report outpatients and carried out limited levels of contact tracing in 77 several provinces (see Fig. 1b). However, despite the growing testing capacity, since the 78 79 government announced plans for re-opening high-risk activities in late May, the second peak in new cases emerged and the number of outpatients started to shrink over time. This raised 80 concerns that, like the first peak when hospitals in many provinces were at near maximum 81 capacity, the degree of under-reporting in both prevalence and deaths has raised substantially 82 higher again. Another point of concern is that the rate of false-negative detection of SARS-CoV-2 83

by RT-PCR tests can get significantly higher over time as the delay from the onset of symptoms

to testing increases. Therefore, by the time tests are taken from hospitalised cases of COVID-19,

there could be typically 3 to 7 days past since the onset of their symptoms and, as a result, a

significant portion of their tests (up to 50%) may come out as negative [7,20].

In this study, we provide a detailed analysis of the COVID-19 outbreak in Iran. By gathering genetic and air travel data from passengers with a link to Iran, we estimate the start date of the epidemic and its prevalence across the country. Coupling this with the estimated number of excess deaths and other key clinical and epidemiological information, such as the age-stratified infection fatality ratios and delays from onset of infection to death, enables us to reconstruct the full transmission dynamics of COVID-19 despite significant levels of under-reporting in prevalence and deaths.

First, we investigate the possibility of data manipulation on reported number of cases and deaths 95 by MoHME using Benford's law. We then use epidemiological and genetic data from air travelers 96 97 with a travel history to Iran along with the first whole-genome sample obtained from inside the country to determine the start date and early growth rate of the epidemic. Next, we provide a 98 province-level analysis on the pattern of spread during winter and spring, highlighting the degree 99 100 of under-reporting in both point prevalence and deaths. We also assess the risk of importation of infected individuals from China into the country from January to mid-March 2020. Finally, we 101 evaluate the impact of non-pharmaceutical interventions (NPIs) on the growth rate of the 102 epidemic and use an SEIR model to evaluate its burden on the healthcare system over the course 103 104 of the outbreak.

105 **Results**

106 Investigating data manipulations using Benford's law

By comparing the reported prevalence and deaths in several countries with sizable outbreaks from 107 mid-February to early-April, we find that many countries, including Iran, were initially on an 108 exponential growth trajectory (see Fig. 2a and 2b). Depending on the testing strategy of each 109 country, i.e. whether they only test hospitalised patients or also allow testing for outpatients, we 110 would expect the reported death toll to follow the same trend as confirmed cases with a few days 111 of delay. However, since 22 March, after passing a total of 1,000 confirmed deaths, Iran's 112 113 reported death toll changed course to a linear growth despite the fact that the number of cases were still growing exponentially up to 2 April. This appeared in stark contrast with many other 114 countries with large outbreaks and raised concerns over the credibility of the reports from Iran 115 and possible manipulation of data by MoHME. We investigate the latter using Benford's Law 116 (see Methods section). Fig. 2c shows the distribution of leading digits in reported cases and deaths 117 during the exponential phase of the outbreak (see Fig. 2a and 2b) for Iran, USA, and UK which 118 119 we compare to the Benford distribution. The result shows that the distribution of leading digits in all the three countries are similar to Benford's distribution and that there is no evidence to suggest 120 a manipulation of data has occurred in any of the examined data sets. It is likely that the apparent 121 122 discrepancy in MoHME's reported numbers is due to delayed turnaround times at the peak of the outbreak when hospitals in several provinces were at near maximum capacity. Prioritising testing 123 for active cases over post-mortem testing of suspect cases is also likely to have contributed to the 124 125 observed difference in trends.

127 Origins of the epidemic in Iran: a phylogenetic analysis

Since the virus spread undetected during the initial phase of the Iranian epidemic, no 128 epidemiological information is available for this phase. Molecular epidemiology provides a 129 powerful tool to reconstruct the early epidemic trajectory a posteriori, especially when direct 130 epidemiological data are absent, incomplete or biased. The 16 March report from NextStrain 131 showed that sequences from cases with a travel history to Iran correspond to a distinct clade of 132 SARS-CoV-2 [21] and that they were phylogenetically related to the dominant variant circulating 133 in Wuhan at the time (prototype strain MN908947/SARS-CoV-2/Wuhan-Hu-1) [22] - see Data 134 S1 for the full list of genome metadata used for this analysis. We first construct a maximum 135 likelihood phylogenetic tree of all sequences that were linked to Iran (see Fig. 3a). We then use 136 these genomic sequences to determine the time to the most recent common ancestor (TMRCA) of 137 the sequences and characterise the initial epidemic growth rate in Iran (see Methods section). 138 Consistent with other studies [23,24], our inferred substitution rate is 1.66×10^{-3} (95% Highest 139 Posterior Density (HPD): $2.18 \times 10^{-4} - 3.31 \times 10^{-3}$) per site per year and the exponential growth 140 rate of 82 in units of years, corresponding to a doubling time of around 3 days (95% 141 HPD:1.68-16.27), which is close to the growth rate in the initial phase of European COVID-19 142 epidemics [56]. The age of the root is placed on 21/01/2020 (95% HPD: 05/12/2019 -143 144 14/02/2020), a month earlier than the first reported case.

145 Estimating the under-reporting of incidence using air-travel data

High levels of under-reporting have been noticed in several countries during the early phase of the 146 COVID-19 pandemic. Such under-reporting creates biases that hinders direct estimates of the 147 148 actual incidence of the disease and are likely to be present in MoHME's report as well. A more reliable estimate of the size of the Iranian epidemic can be obtained from the number of exported 149 cases detected abroad [57575757]. In late February, a total of 8 internationally exported cases of 150 COVID-19 with direct flights from Iran were detected in Lebanon, UAE, Oman, and Kuwait. 151 Similarly, in early March, an additional 28 cases were identified in China (see Table 1). By 152 finding the approximate number of passengers per week travelling from Iran to these countries, 153 we use a binomial likelihood estimation method (see Methods section) to estimate the nationwide 154 incidence (see Fig. 3b). Our result suggests the number of infectious individuals by 25 February is 155 18,500 (95% CI: 11,400 - 30,700) and 259,500 (95% CI: 199,200 - 356,200) 6 March which is 156 157 aligned with estimated outbreak size from other studies [25,26] and is more than 100 times higher than confirmed cases that MoHME reported at the time – see the sensitivity analysis on the 158 parameters of our model in Table S2. These estimates also suggest a doubling time of 2.6 days 159 (approximate 95% CI: 2.2-3.3 days), which is remarkably consistent with the range observed in 160 161 many other countries with major outbreaks (2.5 - 3.5 days). We then use this range of doubling times to extrapolate the number of cases back in time and find 13/01/2020 (05/01/2020 -162 25/01/2020) to be the approximate start date of the epidemic, which is also well aligned with the 163 estimated root age of our phylogenetic analysis. 164

165 Estimating the under-reporting of cumulative deaths using excess mortality data

166 Given the high levels of under-reporting, excess mortality data represent a more reliable source to

167 estimate COVID-19 related deaths. By analysing the seasonal reports from the National

168 Organization for Civil Registration (NOCR) of Iran on province-level all-cause deaths, we find

that four provinces in winter and twenty-six provinces in spring 2020 had significantly higher

170 recorded deaths compared to previous years (see Fig.4a and 4b). During winter, the four

provinces in central and northern Iran (Qom, Gilan, Golestan, and Mazandaran) showed a 27% 171 rise in mortality with 3,476 (95% CI: 3,172 - 3,779) deaths in excess of previous years. In spring, 172 our estimates show a 22% increase with a total of 17,242 (95% CI: 15,687 - 18,797) excess 173 deaths in twenty-six provinces compared to previous years. Oom and Gilan, two of the hardest-hit 174 provinces in winter, show a lower percentage of excess deaths in spring possibly indicating that 175 the largest part of their outbreak occurred back in winter while in many other provinces such as 176 Mazandaran, Khuzestan, and Oazvin the excess deaths continued to increase during spring. This 177 is also corroborated by numerous reports from various provinces across the country and is aligned 178 with the fact that the first nationwide epidemic peak occurred in late-March. 179

180 Early-stage importation risk from China

The Iranian epidemic was most likely seeded by one or more imported cases flying from China. 181 Given the debate on travel restrictions, it is worth assessing what was the actual early-stage risk of 182 imported cases in Iran. We match the air travel data from infected passengers travelling via flights 183 from Beijing, Shanghai, and Guangdong with the prevalence data from China (see Methods 184 section) and find that the expected number of imported cases to Iran from 22 January to 15 March 185 remained very low, with just one imported case expected across the whole period. The fact that 186 187 the epidemic took over despite the low number of importations from China and the strong overdispersion in transmissions suggests that infected individuals likely belong to a high-risk sub-188 group of the population, such as businessmen, politicians, or other individuals who frequently 189 travel to the country and tend to meet a large number of contacts. 190

191 Evaluating effectiveness of intervention measures and the dynamics of the outbreak

We first evaluate the effectiveness of key NPIs (see Methods section) implemented on set dates in 192 Iran and their impact on reducing the effective reproduction number, Rt (Table 2 and Figure 5a). 193 Our analyses indicate that while intervention measures, particularly the nationwide lockdown 194 during the New Year's holiday month, were effective in curbing the spread (Rt < 1), the 195 reopening of high-risk businesses in May led to the emergence of a new peak of infection across 196 the country (Rt > 1). They also suggest that mandatory face covering in public spaces can be 197 198 effective enough to stop the exponential growth pattern (Rt < 1) and reduce the transmission rates 199 by late-July/early-August conditioned on having no other major change in NPIs or social behaviour (e.g. travelling for holidays or mass gatherings) during this time period. The model 200 successfully recreates the nationwide trend of the outbreak with one peak in deaths during late 201 March and a second emerging peak that started back in late May due to relaxed NPI measures 202 (see Figure 5b and 5c). Our model correctly forecasted the insurgence of the second epidemic 203 204 peak [18]. Also, our estimates for point-prevalence and cumulative deaths are aligned with those we predicted based on air travel and excess mortality. Our results suggest, cumulatively, that 9.04 205 (95% CI: 0.147 – 43.65) million people have recovered and 26.14 (95% CI: 0.53 – 155.22) 206 207 thousand died as of 14 July 2020. Both the first peak in March and the second peak in July has very likely overwhelmed the healthcare system with approximately 8.70 (95% CI: 0.55 - 85.85) 208 thousand severely ill patients during the peak weeks and 0.474 (95% CI: 0.031 - 4.8) million 209 infectious at the peak of the epidemic (see Data S5). We note the large variation in the results is 210 due to variations in the effective reproduction number, Rt, and its significant impact on the 211 growth dynamics of the epidemic. The upper bound in the simulation results corresponds to an 212 initial reproduction number of Rt = 5 in which case most infections and deaths take place during 213 the first peak in late March and Rt never goes below 1 throughout the simulation (population 214 reaches herd-immunity threshold by mid-June) while the lower bound assumes an initial 215

reproduction number Rt = 2.5 with a very mild first peak in March after which Rt remains below

1 and no second peak will emerge.

218 Materials and Methods

219 Data on aggregate number of cases and deaths

We use the time series data for the number of confirmed cases and deaths (see Data S2) from the John Hopkins University Centre for Systems Science and Engineering COVID-19 GitHub repository (accessed on 04/06/2020). We also obtain time series data on confirmed cases in all the 31 provinces of Iran from the ministry of health website (*behdasht.gov.ir*). We note that ministry stopped releasing province data from Mar 23 onward. They also did not release province data on Mar 2 and 3. We obtain mortality statistics from the National Organization for Civil Registration of Iran (*sabteahval.ir*).

227 Benford's law

Benford's law (BL) defines a probability distribution for the leading digits in a determined set of numbers [27]. The probability that a digit, d = 1, 2, ..., 9, is a leading number is given by $P(d) = \log_{10}(1+(1/d))$ where numbers with leading digit 1 have the highest probability of appearance and this probability steadily decreases as the starting digit becomes larger. BL is used in a variety of fields such as accounting, trade, and election results to study possible fraud and irregularities with data [28-30] and is also frequently used to assess the quality of epidemiological and clinical data [31-33].

In the early phase of an outbreak when the number of reported cases and deaths grow 235 exponentially, a function of the form $2^{t/T}$ exactly obeys the BL distribution, where t is the unit of 236 time (measured in days) and T is the doubling time in new cases/deaths. If we combine two data 237 238 sets with different growth rates into one larger data set, the numbers in the larger data set still obey the BL distribution. In the context of the COVID-19 outbreak, we can examine possible 239 manipulation of data by comparing the probability distribution of the leading digits in the reported 240 number of cases and deaths from different countries to BL distribution. We note that while this 241 method can be used to test if data manipulation has occurred, it does not provide any information 242 about deliberate absence of data by, for instance, not reporting deaths from certain hospitals. 243

244 Phylogenetic analysis

We obtain the first whole-genome sequence of SARS-CoV-2 from inside Iran and collect an 245 additional 20 sequences from cases that flew out of Iran and had their viral genomes determined 246 in other countries. Two of these sequences are epidemiologically linked and cannot be used for 247 the purpose of join-inference of TMRCA and doubling times. Thus, we use the remaining 19 248 whole-genome sequences to infer parameters of the epidemic using the phylogenetic software, 249 BEAST [34]. We use the known sampling times with a Continuous-Time Markov Chain 250 reference prior on the substitution rate, an exponential population coalescent model with a 251 lognormal prior on size (mean=1, SD=2), Laplace prior on growth rate (scale=100), and an 252 HKY+G substitution mode [23,24] and allow the Markov chain Monte Carlo to run for a hundred 253 million steps and discard the first 10% steps as burn-in. Effective sample sizes of all parameters 254 are >1,000 ensuring that they are well-sampled. We also construct the maximum likelihood tree 255 of all sequences using PhyML [35]. 256

258 Estimating the number of active cases using air travel data

We estimate the number of passengers from four of the busiest airports in Iran (Tehran, Mashhad, 259 Isfahan, and Shiraz) who flew to Oman, Lebanon, UAE, Kuwait, and China (see Data S3). We 260 allow for 50% (20% - 100%) of the 55 million residents in provinces near the airports to represent 261 their catchment population size (see Data S4). There is typically 5 (4-6) days of incubation period 262 [7-9,36,37] and an additional 5 (3-7) days of delay from symptom onset to detection [38,39]. We 263 further assume that an additional 45% (30%-55%) of asymptomatic and 15% (10%-25%) mildly-264 symptomatic cases were among the confirmed exported carriers of COVID-19 [40,41]. Thus, the 265 probability of having an infected individual on board the aircraft is given by p = Dt / M, where D 266 is the daily passenger flux, M is the catchment population size, and t is the exposure time which is 267 the sum of incubation period and delay to symptom onset to detection. Finally, to estimate the 268 number of infectious individuals, λ_i , for country, *i*, with n_i detected cases and probability of 269 successful detection, p_i , we can maximise the likelihood function given by 270

271
$$L = \arg \max_{\lambda_i} \begin{pmatrix} \lambda_i \\ n_i \end{pmatrix} p_i^{n_i} (1 - p_i)^{\lambda_i - n_i}$$

272 Estimating seasonal excess mortality

We use the publicly available data from the NOCR which records the all-cause registered deaths 273 in Iran per province per season in Solar Hijri (SH) calendar [42]. We assembled this data for the 274 last 5 years to compare the excess mortality during winter and spring 2020 to previous years. 275 Excess deaths refer to the number of deaths above expected seasonal baseline levels, regardless of 276 the reported cause of death, and can be used as a nonspecific measure of the severity of the 277 epidemic and provide a more accurate measure of its burden on the healthcare system [43]. We 278 analyse the NOCR data from 1394 SH to 1399 SH (from 22 December 2015 to 20 June 2020 in 279 the Gregorian calendar). For each province, we apply a least-square regression model on the 280 seasonal deaths from previous years to find the 'expected' seasonal death in 2020 (see Fig. S1 and 281 S2) and then calculate the difference with respect to the observed death toll for each province to 282 find excess mortality (see Table S2 and S3). We attribute excess deaths in those provinces with 283 significant deviations (i.e. three standard deviation units) with respect to their expected seasonal 284 value to COVID-19-related deaths. 285

286 Evaluating the importation risk of new cases from China in January

We define the importation risk as the mean number of infectious individuals travelling from 287 China to Iran over the span of approximately three months, from the start of the outbreak in China 288 until mid-March. We assume importations to Iran only occur via air travel from infected areas in 289 China. The main routes of travel to Iran are from airports in Beijing, Shanghai, and Guangdong. 290 We allow a fraction, f, of passengers to come from the Hubei province. To calculate f we take the 291 ratio of total passenger traffic from airports in Hubei to 100 busiest airports across the country 292 according to the 2018 report from the Civil Aviation Administration of China [44]. We further 293 assume that only pre-symptomatic or asymptomatic cases travelled to Iran. The probability that an 294 individual on board the plane is infected can be given by 295

296
$$p(t) = \sum_{k=0}^{\infty} 10(1 - S(k))i(t+k) / N$$

where i(t) is the incidence of cases in a given province at time t, N is the population size of the province, and S(k) is the CDF of the incubation period and is assumed to be log-normally distributed (mean=4.8 days, SD=1.9 days) [37]. The factor 10 is to correct for the true incidence by accounting for an additional 90% unascertained infections before mid-March in China [45]. Finally, to calculate the expected number of imported cases from 22 January to 15 March, we have

303

306

$$\sum_{i=\{Beijing, Shanghai, Guangdong\}} \sum_{t=0}^{53} (1-f)c_i p_i(t) + fc_{Hubei} p_{Hubei}(t) \approx 1$$

where t=0 corresponds to 22 January and c_i is the average number of passengers flying from province *i* per day.

307 SEIR model

We use a generalised SEIR model with age-stratified compartments to approximate the dynamics 308 of the epidemic [46]. In this model, susceptible individuals can be exposed to the virus through 309 contact with an infected individual. They then progress towards the infectious stage where they 310 can either recover without hospitalisation or progress towards sever illness that requires 311 hospitalisation. For the latter group, individuals either recover or transition to the ICU stage at 312 which point they either die or return back to the hospitalisation state. The effective reproduction 313 number, Rt, is modelled as a piecewise constant function that changes immediately upon a new 314 NPI. In the absence of mobility data from Iran, we make the assumption that the efficacy of 315 individual interventions from other countries are the same as those implemented in Iran and that 316 they remain constant over time (see Table 2). Other studies have shown broad equivalency in the 317 effect of reductions in different types of mobility and their corresponding impact on Rt [47-49]. 318 We note that the dynamics of the epidemic, like any other exponentially growing process, is most 319 sensitive to the growth rate. Thus, we allow for a relatively broad range in basic reproduction 320 number, R_0 , and the efficacy of NPIs to appropriately capture the uncertainties in the dynamics. 321 Furthermore, the model relies on fixed estimates of some epidemiological parameters such as age-322 323 stratified infection fatality ratio, latency period, and infectious period based on other studies (see Table 3). The duration of hospital/ICU stay is taken from the 14 March report by MoHME (see 324 325 Fig. S3) [50], and the simulation start date is based on our analysis of exported cases (see Fig. 3b). We assume all infected individuals are immune to reinfection over the course of the 326 simulation. 327

328

329 Discussion

Using various clinical, epidemiological, and genetic information, we reconstructed the outbreak 330 of SARS-CoV-2 in Iran in the presence of significant levels of under-reporting of prevalence and 331 deaths. We showed that Benford's law can be used as a statistical test to investigate possible 332 manipulation of reported data during the exponential phase of the epidemic. We then examined 333 the burden of the outbreak on 31 provinces of Iran during winter and spring 2020 using the 334 seasonal excess mortality data. We find that a large number of provinces did not show signals of 335 significant excess mortality in winter further supporting the observation that the outbreak was still 336 at its early stages during this period with only a few hot-spot provinces. We further showed that 337 air travel data from confirmed exported cases acts as a proxy for measuring the number of active 338 339 cases and that genomic data have the power to provide sensible estimates for the start date of the epidemic and its early doubling times. Phylogenetic analysis, coupled with epidemiological 340

(recent travel to Iran in late February and early March) and clinical data (date of symptom onset), 341 further helped with identification an emergent clade of SARS-CoV-2 linked to cases with a travel 342 history to Iran. The lack of genetic diversity in these samples reflects the early stages of SARS-343 CoV-2 transmissions within Iran and newly identified sequences from Iran are likely to fall in this 344 clade. Other phylogenetic analyses have shown that these sequences are also closely related to 345 three Chinese strains sampled in mid-January from Hubei, Shandong, and Guangdong 346 (Wuhan/HBCDC-HB-05/2020, Shandong/IVDC-SD-001/2020, and Guangdong/DG-S41-347 P0056/2020) indicating that the first imported case to Iran likely came from mainland China 348 [21,22]. The overall low importation rate of new cases from China based on incidence data 349 suggests that importation to Iran likely occurred via a high-risk individual with frequent travels to 350 351 the country.

In this study, we found no significant evidence of data manipulations based on Benford's law. 352 353 However, this test alone cannot be used to rule out some systematic or random patterns of absence of data on case or death counts, e.g. from certain hospitals. The number of confirmed COVID-19 354 cases in each country may vary depending on the transparency to report correct statistics and the 355 capacity of the healthcare system to detect new cases. The latter also depends on the accuracy of 356 laboratory test kits and accessibility of diagnostic and screening tests. Indeed, many countries 357 with limited testing capacities may have to prioritise testing that informs policy decisions, e.g. 358 they may not test suspected cases with mild symptoms or those who are asymptomatic and are a 359 close contact of a confirmed case. As a result, the true number of cases is always many times 360 higher than those reported by the health agencies. In addition, the burden of the epidemic can 361 significantly impact the performance of the healthcare system to properly allocate cause of deaths 362 in individuals with underlying health conditions such as diabetes or heart disease. Therefore, 363 tracking all-cause registered deaths and estimating excess mortality during the outbreak provides 364 a more sensitive measure of COVID-19-associated deaths than would be recorded by counting 365 confirmed or suspect deaths. We note that all-cause deaths may also include factors that are not 366 causally associated with SARS-CoV-2 that might affect death rates such as the circulation of the 367 2019-20 seasonal influenza. According to the United Nations Statistical Division the estimated 368 coverage of registered deaths in Iran is 92% [51] which could potentially be suffering even more 369 from under-counting during the peak of the outbreak when there are likely going to be further 370 delays in death registrations. Also, excess seasonal mortality does not take into account the 371 catalysing role of COVID-19 in deaths among individuals with underlying comorbidities who 372 373 would have likely died during a particular season even without contracting COVID-19 (as part of the 'background' deaths). 374

Despite integrating multiple sources, our data have many limitations. We investigated air travel 375 data only to countries with direct flights to Iran and discarded information from detected cases in 376 countries such as Qatar and Canada since we were not able to independently verify the fraction of 377 passengers on board the planes who travel from Iran to those countries. Also, given the lack of 378 mobility data from Iran, we were unable to investigate possible international exportation of cases 379 to Afghanistan, Iraq, Syria, Azerbaijan, Turkey, and other countries with a significant flow of 380 ground transportation (i.e. trains, buses, and cars) from Iran. We did not have access to the 381 province-level number of confirmed COVID-19 deaths which is a significant source of 382 information to assess excess deaths in the winter and spring 2020. Also, there is likely extreme 383 heterogeneity in the geographical spread of COVID-19 across the country due to various factors 384 such as demographic structure of the provinces' populations, the pattern of social contacts 385 between age groups, and the quality of healthcare and effectiveness of NPIs in different districts. 386

Our SEIR modelling analysis shows that in the most likely scenario by mid-July only 11% of the 387 population have recovered from the disease which implies that a large fraction of the population is 388 still vulnerable to contracting COVID-19. We also find strong indications that the outbreak was 389 never brought under control since it emerged back in mid-January. This has significant 390 implications both for the likely chance of the virus becoming endemic to the country and its likely 391 return during winter this year which, if coupled with seasonal flu, can significantly overwhelm the 392 hospitals. Furthermore, the continuation of under-reporting in prevalence due to limited testing of 393 suspect cases and tracing their contacts will likely lead to several undetected superspreading 394 events that can spark new outbreaks in different parts of the country making nowcasting and 395 forecasting of the COVID-19 epidemic in Iran extremely challenging. 396

398 **References**

- 399 1. World Health Organization, Coronavirus disease 2019 (COVID-19): situation report, 176,400 (2020).
- 2. WHO Director-General's opening remarks at the media briefing on COVID-19 28 February
 2020 [Link to the report].
- 403 3. *behdasht.gov*. Retrieved 28 February 2020 [Link to the report].
- 404 4. Wright, R., How Iran became a new epicenter of the coronavirus outbreak. The New Yorker,
 405 2020 [Link to the report].
- 5. Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., and Shaman, J., Substantial
 undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*, 368, 489-493 (2020).
- 6. Pybus, O. G., Rambaut, A., and COG-UK-Consortium, Preliminary analysis of SARS-CoV-2
 Importation & Establishment of UK Transmission Lineages. *Viroglocal.org* (2020).
- 411 7. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al., Early transmission dynamics in
- Wuhan, China, of novel coronavirus–infected pneumonia. *New England Journal of Medicine*, 82, 1199-1207 (2020).
- 414 8. Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S.,
- 415 Reich, N. G., and Lessler, J., The incubation period of coronavirus disease 2019 (COVID-19)
- 416 from publicly reported confirmed cases: estimation and application. *Annals of internal* 417 *medicine*, **172**, 577-582 (2020).
- 9. Ganyani, T., Kremer, C., Chen, D., Torneri, A., Faes, C., Wallinga, J. and Hens, N., Estimating
 the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March
 2020. *Eurosurveillance*, 25, 2000257 (2020).
- 10. Oran, D. P. and Topol, E. J., Prevalence of Asymptomatic SARS-CoV-2 Infection: A
 Narrative Review. *Annals of Internal Medicine*, M20-3012 (2020).
- 11. Buitrago-Garcia, D. C., Egli-Gany, D., Counotte, M., J., Hossmann, S., Imeri, H., Ipekci, A.
- 424 M., Salanti, G., and Low, N., The Role of Asymptomatic SARS-CoV-2 Infections: Rapid Living 425 Systematic Review and Meta-Analysis. *medRxiv*, 2020.04.25.20079103 (2020).
- 426 12. Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D. Y., Chen, L., and Wang, M., Presumed 427 asymptomatic carrier transmission of COVID-19. *JAMA*, **323**, 1406-1407 (2020).
- 428 13. Silverman, J. D., Hupert, N., Washburne, A. D., Using influenza surveillance networks to 429 estimate state-specific prevalence of SARS-CoV-2 in the United States. *Science Translational*
- 430 *Medicine*, **12**, eabc1126 (2020).
- 431 14. Ferretti, L., Wymant, C., Kendall, M., Zhao, L., Nurtay, A., Abeler-Dörner, L., Parker, M.,
 432 Bonsall, D. and Fraser, C., Quantifying SARS-CoV-2 transmission suggests epidemic control
- Bonsall, D. and Fraser, C., Quantifying SARS-CoV-2 transmiss
 with digital contact tracing. *Science*, **368**, eabb6936 (2020).
 - 434 15. World Health Organization, Influenza situation in the Eastern Mediterranean Region,
 435 W11/2020 [Link to the report].

- 436 16. Ghafari, M., Madani, K., In search of the murder: Making sense of Iran's reported deaths,
 437 *Medium* (2020) [Link to the report].
- 438 17. World Health Organization, WHO ships emergency medical supplies to the Islamic Republic
 439 of Iran, 12 March (2020) [Link to the report].
- 18. Ghafari, M., Hejazi, B., Karshenas, A., Dascalu, S., Ferretti, L., Ledda, A., Katzourakis, A.,
 Ongoing outbreak of COVID-19 in Iran: challenges and signs of concern. *medRxiv*,
 2020.04.18.20070904 (2020).
- 19. Russell, T. W., Hellewell, J., Abbott, S., Jarvis, C. I., van Zandvoort, K., CMMID nCov
 working group, Flasche, S., Eggo, R. M., Edmunds, W. J., Kucharski, A. J., Using a delayadjusted case fatality ratio to estimate under-reporting. *Centre for Mathematical Modeling of Infectious Diseases Repository*, Last update: 24-07-2020.
- 447 20. Wikramaratna, P., Paton, R. S., Ghafari, M., Lourenco, J., Estimating false-negative detection 448 rate of SARS-CoV-2 by RT-PCR. *medRxiv*, 2020.04.05.20053355 (2020).
- 449 21. Hodcroft, E., Müller, N., Wagner, C., Ilcisin, M., Hadfield, J., Bell, S. M., Neher, R., Bedford,
- 450 T., Genomic analysis of COVID-19 spread. Nextstrain Situation Report 2020-03-13 [Link to the
- 451 <u>report</u>].
- 452 22. Eden, J. S., Rockett, R., Carter, I., Rahman, H., De Ligt, J., Hadfield, J., et al., An emergent
- 453 clade of SARS-CoV-2 linked to returned travellers from Iran. *Virus Evolution*, **6**, veaa027 (2020).
- 454 23. Rambaut, A., Phylogenetic analysis of nCoV-2019 genomes. *Viroglocal.org* (2020).
- 455 24. Boni, M. F., Lemey, P., Jiang, X., Lam, T. T. Y., Perry, B., Castoe, T., et al., Evolutionary
 456 origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic.
 457 *bioRxiv*, 2020.03.30.015008 (2020).
- 458 25. Tuite, A. R., Bogoch, I. I., Sherbo, R., Watts, A., Fisman, D., and Khan, K., Estimation of 459 coronavirus disease 2019 (COVID-19) burden and potential for international dissemination of 460 infection from Iran. *Annals of Internal Medicine*, **172**, 699-701 (2020).
- 461 26. Zhuang, Z., Zhao, S., Lin, Q., Cao, P., Lou, Y., Yang, L., and He, D., Preliminary estimation 462 of the novel coronavirus disease (COVID-19) cases in Iran: A modelling analysis based on 463 overseas cases and air travel data. *International Journal of Infectious Diseases*, **94**, 29-31 (2020).
- 464 27. Benford, F., The law of anomalous numbers. *Proceedings of the American philosophical* 465 *society*, **78**, 551-572 (1938).
- 466 28. Cerioli, A., Barabesi, L., Cerasa, A., Menegatti, M., and Perrotta, D., Newcomb-Benford law
- and the detection of frauds in international trade. *Proceedings of the National Academy of Sciences*, **116**, 106-115 (2019).
- 29. Pericchi, L., and Torres, D., Quick anomaly detection by the Newcomb—Benford Law, with
 applications to electoral processes data from the USA, Puerto Rico and Venezuela. *Statistical*
- 471 *science*, **26**, 502-516 (2011).
- 472 30. Durtschi, C., Hillison, W., and Pacini, C., The effective use of Benford's law to assist in
- detecting fraud in accounting data. *Journal of forensic accounting*, **5**, 17-34 (2004).


- 474 31. Idrovo, A. J., and Manrique-Hernández, E. F., Data Quality of Chinese Surveillance of 475 COVID-19: Objective Analysis Based on WHO's Situation Reports. *Asia-Pacific Journal of*
- 475 COVID-19: Objective Analysis Based
 476 *Public Health*, **32**, 165-167 (2020).
- 477 32. Crocetti, E., and Randi, G., Using the Benford's law as a first step to assess the quality of the 478 cancer registry data. *Frontiers in public health*, **4**, 225 (2016).
- 479 33. Idrovo, A. J., Fernández-Niño, J. A., Bojórquez-Chapela, I., and Moreno-Montoya, J.,
- 480 Performance of public health surveillance systems during the influenza A (H1N1) pandemic in
- the Americas: testing a new method based on Benford's Law. *Epidemiology & Infection*, 139,
 1827-1834 (2011).
- 34. Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J., & Rambaut, A.,
 Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus evolution*, 4,
 vey016 (2018).
- 486 35. Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O., New 487 algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance
- 488 of PhyML 3.0. Systematic biology, **59**, 307-321 (2010).
- 489 36. He, X., Lau, E. H., Wu, P., Deng, X., Wang, J., Hao, X., et al., Temporal dynamics in viral 490 shedding and transmissibility of COVID-19. *Nature medicine*, **26**, 672-675 (2020).
- 37. Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., et al., Epidemiology and transmission of
 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective
 cohort study. *The Lancet Infectious Diseases*, 10.1016/S1473-3099(20)30287-5 (2020).
- 494 38. World Health Organization, Novel Coronavirus Thailand (ex-China). 14 January 2020 [Link
 495 to the report].
- 496 39. Ministry of Health, Labour and Welfare Japan,
 497 新型コロナウイルスに関連した肺炎の患者の発生について(1例目). 16 January 2020
 498 [Link to the report].
- 499 40. Lavezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Del Vecchio,
- 500 C., et al., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*, 501 04.17.20053157 (2020).
- 41. Casey, M., Griffin, J., McAloon, C. G., Byrne, A. W., Madden, J. M., McEvoy, D., et al., Presymptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv*,
 2020.05.08.20094870 (2020).
- 42. National Organization for Civil Registration, Registered Deaths by Province. *Sabteahval.ir* (Accessed in June 2020) [Link to the report].
- 43. Olson, D. R., Huynh, M., Fine, A., Baumgartner, J., Castro, A., Chan, H. T., et al.,
 Preliminary estimate of excess mortality during the COVID-19 outbreak New York City, March
 11–May 2, 2020. *CDC MMWR*, **69** (2020).
- 510 44. Civil Aviation Administration of China, **年民航机**场生产统计公报. 5 March 2020 [Link to 511 the report].
- 45. Hao, X., Cheng, S., Wu, D., Wu, T., Lin, X., & Wang, C. (2020). Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature*, 10.1038/s41586-020-2554-8 (2020).

- 46. Noll, N. B., Aksamentov, I., Druelle, V., Badenhorst, A., Ronzani, B., Jefferies, G., Albert, J.,
- 515 Neher, R., COVID-19 Scenarios: an interactive tool to explore the spread and associated 516 morbidity and mortality of SARS-CoV-2. *medRxiv*, 2020.05.05.20091363 (2020).
- 47. Flaxman, S., Mishra, S., Gandy, A., Unwin, H. J. T., Mellan, T. A., Coupland, H., et al.,
- 518 Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature,
- 519 10.1038/s41586-020-2405-7 (2020).
- 48. Mellan, T. A., Hoeltgebaum, H. H., Mishra, S., Whittaker, C., Schnekenberg, R. P., Gandy, A., et al., Report 21: Estimating COVID-19 cases and reproduction number in Brazil. *medRxiv*, 2020.05.09.20096701 (2020).
- 49. Unwin, H., Mishra, S., Bradley, V. C., Gandy, A., Vollmer, M., Mellan, T., et al., Report 23:
 State-level tracking of COVID-19 in the United States. *Imperial London College Report*, 10.25561/79231 (2020).
- 526 50. National Committee on COVID-19 Epidemiology, Daily Situation Report on Coronavirus 527 disease (COVID-19) in Iran. 14 March 2020 [Link to the report].
- 528 51. United Nations Statistical Division, Demographic and Social Statistics. *unstats.un.org* 529 (Accessed in June 2020) [Link to the report].
- 52. Candido, D. S., Claro, I. M., de Jesus, J. G., Souza, W. M., Moreira, F. R., Dellicour, S., et al.,
 Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science*, 10.1126/science.abd2161
 (2020).
- 533 53. Eikenberry, S. E., Mancuso, M., Iboi, E., Phan, T., Eikenberry, K., Kuang, Y., et al., To mask 534 or not to mask: Modeling the potential for face mask use by the general public to curtail the 535 COVID-19 pandemic. *Infectious Disease Modelling*, **5**, 293-308 (2020).
- 536 54. Surveillances, Vital, The epidemiological characteristics of an outbreak of 2019 novel 537 coronavirus diseases (COVID-19) – China, 2020. *China CDC Weekly*, **2**, 113-122 (2020).
- 538 55. Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., et al., Estimates of
 539 the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*,
 540 20, 669-677 (2020).
- 541 56. Pellis, L., Scarabel, F., Stage, H. B., Overton, C. E., Chappell, L. H., Lythgoe, K. A., et al.,
- 542 Challenges in control of Covid-19: short doubling time and long delay to effect of 543 interventions. *medRxiv*, 2020.04.12.20059972 (2020).
- 544 57. Imai, N., Dorigatti, I., Cori, A., Donnelly, C., Riley, S., and Ferguson, N., Report 2: 545 Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. *Imperial*
- 546 College London COVID-19 Response Team (2020).
- 547

Acknowledgments: Funding: MG and SD are funded by the Biotechnology and Biological 548 Science Research Council (BBSRC), grant number BB/M011224/1. Author contributions: MG, 549 AL, and AK conceptualised and developed the work. MG wrote the manuscript and all other 550 authors reviewed and edited the manuscript. BH and MG investigates data manipulation and 551 carried out the Benford analysis. AKar collected the air travel data for confirmed exported cases. 552 AKar and MG analysed the air travel data to measure incidence across the country. AKad and 553 MG collected and analysed the excess mortality data. MAK, MA, and SZ collected and validated 554 the genomic sample from Iran. AK and MG collected the remaining 20 genomic sequences from 555 passengers with a travel history to Iran and carried out the phylogenetics analysis. MH and MG 556 collected the data regarding daily reports on testing and set dates for non-pharmaceutical 557 intervention measures. Competing interests: Authors declare no competing interests. Data and 558 materials availability: All data and codes used for the analysis is available online on our GitHub 559 560 repository (github.com/mg878/Iran_study).

562 *Figures*:










Fig. 1. Epidemiological and demographic characteristics of confirmed COVID-19 cases in Iran through time. (A) Total incidence of COVID-19 by province on 22 Mar 2020 (last day that MoHME released province-level daily cases). (B) Number of confirmed hospitalised patients (dark blue) and outpatients (light blue). Red lines show the number of daily tests taken over time. Vertical arrows indicate some of the major interventions or changes of policies.




Fig. 2. Investigating data manipulation on reported number of cases and deaths. (A) and (B) show the number of new cases and deaths over the last seven days with respect to the total number of cases and deaths, respectively. (C) Shows the probability distribution of leading digits in the total number of confirmed cases and deaths from the start of the epidemic in each country during the exponentially growing phase and compare this to the distribution given by Benford's law (BL). We sample 40 random numbers from this data set for each country and count the number of occurrences for the leading digits. To ensure convergence, we repeat this process 50 times. Error bars represent one standard deviation unit away from the mean.

565 566

567




Fig. 3. Phylogenetic and epidemiological analysis on cases with a travel link to Iran. (A) Maximum likelihood phylogenetic tree of samples linked to Iran (including the first sample from inside Iran, HGRC-01-IPI-8206/2020). The labels include the sampling times used in the BEAST analysis. Red labels indicate the two epidemiologically linked samples that were excluded from the subsequent analysis. (B) Estimating the start date of the epidemic and its initial growth trajectory (with a range of doubling times from 2.5 to 3.5 days) based on the likelihood analysis on exported cases to UAE (best case scenario with the lowest estimated number of active cases), Lebanon (worst case scenario with the highest estimated number of active cases), and Kuwait, Oman, and China (see Table 1). The likely scenario is based on the expected number of active cases in late February.

569




Fig. 4. Percentage of excess deaths (with respect to the five-year average) during winter and spring 2020 in 31 provinces of Iran. (A) and (B) show the percentage of excess deaths during winter (from 22 Dec 2019 to 19 Mar 2020) and spring (from 20 Mar to 20 June 2020). Four provinces (highlighted in cyan) during winter and twenty-six provinces (highlighted in green) during spring show significant levels of excess mortality. Gray bars represent provinces with no significant deviations from their five-year average (based on 95% confidence interval). The vertical dashed lines show the mean percentage of excess mortality in each season. During winter, the mean excess mortality is only 2% while in spring this grows to 21% across all provinces.

570




Fig. 5. Reconstructing the epidemic in Iran using an SEIR model. Country-level estimation of infections, deaths, and proportion recovered based on the effect of NPIs on effective reproduction number. (A) Time-varying reproduction number, Rt. Vertical dashed lines correspond to the dates when major intervention measures were implemented (see Table 1). (B) Shows the weekly number of infections (orange line) and estimated number of infections (orange dots) based on confirmed exported cases (with error bars showing the 95% CI). The number of weekly infections estimated by the model drops immediately after an NPI takes into effect. The weekly number of deaths (brown line) follows the same trend as the reported number of deaths (brown dots). (C) Shows the cumulative deaths (purple line) and total number of individuals recovered (green line). The predicted cumulative deaths grow proportionally with respect to cumulative reported deaths (purple dots) and does not reach higher values with respect to the estimated excess mortality during winter and spring (red dots). Lines represent model predictions and shaded areas are 95% confidence intervals.

573 *Tables*:

Table 1. Estimated number of infectious individuals based on air travel data. This includes a list of all countries with confirmed cases of COVID-19 travelling from Iran via direct flights (see Data S3 for more information).

Date	Country	Passengers/week	Reported cases	Estimated active cases (95% CI)
21/02/2020	Tahananl	800	1	(4,000,(10,700, 22(,000))
21/02/2020	Lebanon ¹	800	1	64,000 (19,700 – 236,900)
22/02/2020	UAE ²	13,430	2	7,700 (3,200 – 19,900)
24/02/2020	0	2.00	2	20,000 (16,100, 101,000)
24/02/2020	Oman ³	2,660	2	39,000 (16,100 - 101,000)
25/02/2020	Kuwait ⁴	4,025	3	32,200 (14,400 - 76,000)
	~~		• •	
06/03/2020	China ⁵	4,500	28	259,500 (199,200 - 356,200)

576 ¹Source, ²Source, ³Source, ⁴Source, ⁵Source

Intervention measures	Description	Date effective†	Relative %reduction in Rt (range) ‡	Reference
School & university closure	Implemented in multiple provinces: Tehran, Mazandaran, Qom, Qazvin, Golestan, Gilan, and several others.	22/02/2020	20%	[47]
Nationwide lockdown*	Closure of all schools, universities, sport centres, & holy sites.	05/03/2020	80%	[47]
Re-opening of low- risk businesses	Partial re-opening of certain businesses such as banks and governmental agencies with limited staff.	18/04/2020	70% (60-85)	[47,48]
Re-opening of all businesses	Re-opening of all businesses including shops and restaurants while observing social distancing rules	26/05/2020	60% (50-75)	[48,49]
Mandatory face- covering	Mandatory in all public spaces including public transports, restaurants, & shops	05/07/2020	75% (60-90)	[53]

578 **Table 2.** Timeline of intervention policy announcements and their impact on effective reproduction number.

⁵⁷⁹ *This intervention is followed by the closure of all business across the country due to the Iranian New Year's holiday

580 period which started in the week leading to 19/03/2020 and has the highest impact on reducing Rt.

581 [†]Older interventions end as soon as a new one takes into effect.

582 [‡]The relative reduction in Rt is based on estimates from European countries, USA, and Brazil.

583

585 **Table 3. SEIR model parameters.** We use this information, along with the effectiveness of intervention measures in reducing Rt (Table 1), to run the simulations on *covid19-scenarios.org* dashboard [46].

Age group	Age distribution*	% of all infections that are fatal†	Model parameters	Expected value	Reference
0-9	14,434,000	0.00075	Basic reproduction number	3.75 (2.5-5)	[47-49,52]
10-19	11,812,000	0.0045	Latency period‡	2.5 days	[36,40,41]
20-29	12,254,000	0.009	Infectious period‡	4 days	[36,40,41]
30-39	16,786,000	0.02	Hospital stay	4.5 days	Fig. S3
40-49	11,926,000	0.072	ICU stay	6 days	Fig. S3
50-59	8,281,000	0.25	Imports per day	0	
60-69	5,264,000	1.1	Initial number of cases	1	
70-79	2,264,000	3.1	Simulation start date	13/01/2020	
+80	1,015,000	6.9	Simulation end date	31/08/2020	

*based on annual reports on vital statistics from the Statistical Center of Iran (*amar.org.ir*).

⁵⁸⁸ [†]We use the statistics from the Chinese CDC [54] for age-stratified IFR which are also broadly compatible with

589 estimates from other studies [55].

590 ‡Latency period is the delay from infection to onset of infectiousness. Infectiousness typically starts from 2.5 days

and peaks at 1 day before the onset of symptoms. Together with infectious period, latency period sets the serialinterval [46].

594 Supplementary Materials:

595

596 Movies S1. The spread of the COVID-19 epidemic in Iran. This includes the incidence, total reported cases and 597 deaths in 31 provinces from 19 February to 22 March 2020 (we note that MoHME has not released the province-level 598 data on cases and deaths since 22 March).

Data S1. Genome metadata. We gratefully acknowledge the authors, originating and submitting labs of the
 sequences from GISAID's Database (*gisaid.org*) on which part of our genetic analysis is based.

Data S2. Number of confirmed cases and deaths. This includes a time series data for the number of confirmed cases and deaths in Iran, UK, US, France, Italy, and Spain as well as daily confirmed cases in Guangdong, Shanghai, Beijing, and Hubei.

Data S3. Estimated number of passengers per country per airport. This includes a detailed list of all flights from
 airports in Tehran, Isfahan, Shiraz, and Mashhad to Oman, UAE, Kuwait, Lebanon, and China. The list also includes
 flight numbers which enables us to find the approximate seating capacity based on aircraft model.

610

611 **Data S4. Estimated catchment population size.** This includes the approximate population of 17 provinces that use 612 the 4 airports in Iran for international travels.

613

Data S5. SEIR simulation results. This includes a detailed output of our SEIR modelling (exported from *covid19-scenarios.org* dashboard). The file includes dates, confirmed weekly cases, confirmed weekly deaths, effective reproduction number, severe cases, exposed individuals, infectious individuals, severely ill individuals (hospitalised), individuals in the ICU, weekly fatalities, cumulative recovered, and cumulative fatalities with their corresponding 95% CI (upper and lower bounds).



Fig. S1. Province-level pattern of excess mortality during winter This record covers every registered death over the last five years including last winter (from 22 December 2019 to 19 March 2020). Gray areas show the 95%

- 623 confidence interval.
- 624



Fig. S2. Province-level pattern of excess mortality during spring. This record covers every registered death over the last five years including last spring (from 20 March to 20 June 2020). Gray areas show the 95% confidence

- 627 the last 628 interval.
- 629




Fig. S3. Delay from hospitalization to death in Iran. (A) Delay from hospital admission to hospital death [50]. (B) Comparison of delay from hospitalization to hospital death for patients with (red) and without tracheal intubation (black).

631

632

regarding author list and submitting labs can be found in Data S1.										
GISAID ID	Virus name	Location	Collection date	Travel history						
EPI_ISL_415583	Canada/BC_40860/2020	Canada	2020-03-03	Travel to Iran						
EPI_ISL_413599	Australia/NSW13/2020	Australia	2020-03-04	Travel to Iran						
EPI_ISL_412975	Australia/NSW05/2020	Australia	2020-02-28	Travel to Iran						
EPI_ISL_413213	Australia/NSW06/2020	Australia	2020-02-29	Travel to Iran						
EPI_ISL_413597	Australia/NSW11/2020	Australia	3/2/2020	Travel to Iran						
EPI_ISL_413598	Australia/NSW12/2020	Australia	3/4/2020	Travel to Iran						
EPI_ISL_412965	Canada/BC_37_0-2/2020	Canada	2020-02-16	Travel to Iran						
EPI_ISL_415577	Canada/BC_69243/2020	Canada	2020-02-20	Contact of a case						
EPI_ISL_415579	Canada/BC_25211/2020	Canada	3/2/2020	Travel to Iran						
EPI_ISL_415587	Canada/BC_66353/2020	Canada	3/4/2020	Travel to Iran						
EPI_ISL_415585	Canada/BC_65034/2020	Canada	3/4/2020	Contact of a case						
EPI_ISL_415580	Canada/BC_17397/2020	Canada	2020-02-28	Travel to Iran						
EPI_ISL_415578	Canada/BC_13297/2020	Canada	2020-02-27	Travel to Iran						
EPI_ISL_415581	Canada/BC_02421/2020	Canada	3/1/2020	Travel to Iran						
EPI_ISL_413490	NewZealand/01/2020	New Zealand	2020-02-27	Travel to Iran						
EPI_ISL_414520	Germany/BavPat2/2020	Germany	3/2/2020	Travel to Iran						
EPI_ISL_414476	USA/NY1-PV08001/2020	USA	2020-02-29	Travel to Iran						
EPI_ISL_417444	Pakistan/Gilgit1/2020	Pakistan	3/4/2020	Travel to Iran						
EPI_ISL_419657	Austria/CeMM0004/2020	Austria	3/3/2020	Travel to Iran						
EPI_ISL_414646	Finland/FIN-266/2020	Finland	3/4/2020	Travel to Iran						
EPI_ISL_424349	Iran/HGRC-01-IPI-8206/2020	Iran	2020-09-03	First sequence from inside Iran						

Table S1. SARS-CoV-2 genomes analysed in this study. A complete metadata with additional information regarding author list and submitting labs can be found in Data S1.

637	Table S2. Sensitivity analysis for the number of active cases based on confirmed exported cases.
-----	--

				Ca	Catchment population (M= million individuals)				
Lebanon (21 Feb)			(Fab)	min = 1	11.1M	max = 55.6M			
			reb)		Airpla	ne capacity			
				min = 50%	max = 90%	min = 50%	max = 90%		
re- &	=40%		min = 7	54700 (16700 - 202900)	30000 (8900 - 112300)	277100 (87600 - 1018400)	153500 (48200 - 565400)		
undetected pre- ptomatics	min =	time (days)	max = 13	29000 (8600 - 108800)	15700 (4300 - 60000)	148800 (46700 - 547900)	82300 (25500 - 304000)		
Percentage of undetecte asymptomatics	: 80%	Exposure t	min = 7	54700 (16700 - 202900)	30000 (8900 - 112300)	277100 (87600 - 1018400)	153500 (48200 - 565400)		
Percen	max =		max = 13	29000 (8600 - 108800)	15700 (4300 - 60000)	148800 (46700 - 547900)	82300 (25500 - 304000)		

				Ca	atchment populatio	on (M= million individ	uals)	
UAE (22 Feb)			ob)	min = 1	1.1M	max = 55.6M		
					Airpla	ane capacity		
				min = 50%	max = 90%	min = 50%	max = 90%	
pre- &	-40%		min = 7	5000 (1800 - 14600)	2800 (1000 - 8000)	24800 (9500 - 73200)	13800 (5200 - 40600)	
–	min =40%	time (days)	max = 13	2700 (900 - 7800)	1500 (500 - 4300)	13400 (5100 - 39400)	7400 (2800 - 21800)	
Percentage of undetecte asymptomatics	: 80%	Exposure t	min = 7	6600 (2700 - 17000)	3700 (1500 - 9400)	33100 (14000 - 85500)	18400 (7700 - 47400)	
Perce	max =		max = 13	3600 (1400 - 9100)	2000 (1500 - 5000)	17800 (7500 - 46000)	9900 (4100 - 25500)	

				С	Catchment population (M= million individuals)				
Oman (24 Feb)			'a b)	min =	11.1M	max =	55.6M		
			eD)		Airpla	ine capacity			
				min = 50%	max = 90%	min = 50%	max = 90%		
pre- &	=40%		min = 7	25,100 (9,200 – 74,200)	13,900 (5,100 – 41,200)	125,400 (46,600 – 371,400)	69,700 (25,800 – 206,300)		
q	min =	ime (days)	ime (days)	time (days)	max = 13	13,500 (4,900 – 39,900)	7,500 (2,700 – 22,100)	67500 (25000 - 199900)	37,500 (13,900 – 111,000)
	Percentage of undetecte asymptomatics max = 80% mi	Exposure t	min = 7	33,400 (13,800 – 86,600)	18,600 (7,600 – 48,100)	167200 (69200 - 433400)	92,900 (38,400 – 240,700)		
Perce			max = 13	18,000 (7,400 – 46,600)	10,000 (4,000 – 25,800)	90,000 (37,200 – 233,300)	50,000 (20,600 – 129,600)		

Kuwait (25 Feb)				C	Catchment population (M= million individuals)					
			Fab)	min = 1	11.1M	max = 55.6M				
			rebj		Airpla	ane capacity				
				min = 50%	max = 90%	min = 50%	max = 90%			
pre- &	-40%		min = 7	5,000 (1,800 – 14,600)	2,800 (1,000 – 8,000)	24,800 (9,500 – 73,200)	13,800 (5,200 – 40,600)			
–	min =40%	time (days)	max = 13	2,700 (900 – 7,800)	1,500 (500 – 4,300)	13,400 (5,100 – 39,400)	7,400 (2,800 – 21,800)			
Percentage of undetecte asymptomatics	= 80%	Exposure t	min = 7	6,600 (2,700 – 17,000)	3,700 (1,500 – 9,400)	33100 (14,000 – 85,500)	18400 (7,700 – 47,400)			
Perce	max =		max = 13	3,600 (1,400 – 9,100)	2,000 (1,500 – 5,000)	17800 (7,500 – 46,000)	9900 (4,100 – 25,500)			

-				(Catchment population (M= million individuals)					
China (6 Mar)			(or)	min =	- 11.1M	max = 55.6M				
			ai)		Airplaı	ne capacity				
				min = 50%	max = 90%	min = 50%	max = 90%			
pre- &	=40%		min = 7	197,700 (149,600 – 277,000)	109,800 (83,100 – 153,800)	988,400 (748,400 – 1,385,300)	549,100 (415,700 – 769,600)			
5	min =-	time (days)	max = 13	106,400 (80,500 - 149,100)	59,100 (44,700 – 82,800)	532200 (402900 - 745900)	295,700 (223,800 – 414,300)			
of /m]	80%	Exposure ti	min = 7	252,100 (196,400 - 339,100)	140,000 (109,100 – 188,400)	1260300 (982300 - 1696100)	700,100 (545,700 – 942,200)			
Percentage asy	max =	H	max = 13	135,700 (105,700 - 182,600)	75,400 (58,700 – 101,400)	678,600 (528,900 – 91,3200)	377,000 (293,800 – 507,300)			

Table S2. Excess mortality in 31 provinces during Winter 2020. This record covers every registered death from 22

651 December 2019 to 19 March 2020. Provinces with significantly higher excess deaths compared to previous years are

652	highlighted in cyan.

52 h1gh11 Province	ghted in cyan. Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (Cl 95%)	Excess deaths upper bound (CI 95%)	Significance
Qom	1,583	2,305	723	46%	6	704	741	+
Gilan	4,556	5,937	1,382	30%	86	1,123	1,640	+
Golestan	2,373	2,947	575	24%	30	486	663	+
Mazandaran	4,477	5,274	797	18%	44	666	928	+
Charmahal o Baxtiyari	1,003	1,061	58	6%	50	-91	207	-
Qazvin	1,644	1,728	85	5%	28	0	169	-
Markazi	2,052	2,112	60	3%	89	-208	328	-
Tehran	16,306	16,773	467	3%	399	-731	1,665	-
Isfahan	6,561	6,729	169	3%	212	-467	804	-
Yazd	1,323	1,333	10	1%	18	-43	63	-
Kordestan	1,908	1,912	5	0%	78	-231	240	-
Alborz	3,072	3,070	-2	0%	202	-608	605	-
Hormozgan	1,810	1,799	-11	-1%	105	-326	305	-
North Khorasan	1,243	1,234	-9	-1%	35	-115	97	-
East Azarbayjan	5,811	5,765	-46	-1%	134	-448	356	-
South Khorasan	987	978	-9	-1%	55	-173	156	-
Semnan	962	950	-12	-1%	45	-147	123	-
Kermanshah	2,967	2,899	-68	-2%	115	-412	277	-
Zanjan	1,434	1,396	-38	-3%	84	-291	216	-
Bushehr	1,212	1,178	-34	-3%	28	-117	49	-
Fars	5,994	5,780	-214	-4%	222	-880	453	-
West Azarbayjan	4,198	4,032	-166	-4%	48	-309	-23	+
Hamedan	2,827	2,711	-116	-4%	28	-200	-31	+
Khorasan Razavi	8,168	7,825	-343	-4%	299	-1,240	555	-
Khuzestan	5,809	5,562	-247	-4%	198	-841	347	-
Ardabil	1,864	1,781	-83	-4%	76	-310	144	-
Lorestan	2,418	2,296	-122	-5%	47	-262	19	-
llam	706	633	-73	-10%	45	-209	63	-
Kerman	4,166	3,687	-479	-11%	97	-771	-186	+
Kohgilueh o Boyerahmad	810	710	-100	-12%	49	-246	46	-
Sistan o Baluchestan	3,976	3,390	-586	-15%	352	-1,642	470	-

	Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (Cl 95%)	Excess deaths upper bound (Cl 95%)
	4 Provinces	12,988	16,463	3,476	27%	101	3,172	3,779

Table S3. Excess mortality in 31 provinces during 2020. This record covers every registered death from 20 March to 20 June 2020. Provinces with significantly higher excess deaths compared to previous years are highlighted in green.

97 green. Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (Cl 95%)	Excess deaths upper bound (Cl 95%)	Significance
Qazvin	1,251	2,067	816	65%	103	508	1,123	+
Charmahal o Baxtiyari	766	1,057	291	38%	110	-40	622	-
Kordestan	1,635	2,229	594	36%	207	-27	1,215	-
Mazandaran	4,040	5,449	1,409	35%	65	1,214	1,604	+
Golestan	2,180	2,858	678	31%	95	394	963	+
Khuzestan	4,919	6,395	1,476	30%	242	751	2,201	+
Gilan	4,059	5,258	1,199	30%	38	1,085	1,313	+
Zanjan	1,225	1,585	360	29%	43	232	488	+
Ardabil	1,641	2,105	464	28%	50	314	614	+
Alborz	2,638	3,365	727	28%	47	585	869	+
Isfahan	5,767	7,172	1,405	24%	67	1,204	1,607	+
Tehran	14,421	17,713	3,292	23%	239	2,575	4,008	+
llam	573	692	119	21%	14	76	161	+
Qom	1,511	1,823	312	21%	57	141	483	+
Yazd	1,249	1,496	247	20%	30	157	338	+
East Azarbayjan	5,451	6,485	1,034	19%	126	655	1,414	+
North Khorasan	1,083	1,283	200	18%	49	53	347	+
Kermanshah	2,666	3,132	466	17%	111	133	799	+
Lorestan	2,246	2,611	365	16%	47	223	507	+
Hormozgan	1,449	1,681	232	16%	87	-29	493	-
Semnan	844	977	133	16%	33	34	232	+
Markazi	1,933	2,217	284	15%	65	88	479	+
Khorasan Razavi	7,618	8,665	1,047	14%	235	342	1,752	+
West Azarbayjan	3,818	4,338	520	14%	87	258	781	+
Hamedan	2,605	2,940	335	13%	82	90	579	+
Kohgilueh o Boyerahmad	691	755	64	9%	12	28	100	+
South Khorasan	973	1,054	81	8%	18	27	135	+
Bushehr	963	1,033	70	7%	70	-141	280	-
Sistan o Baluchestan	2,750	2,929	179	7%	124	-193	551	-
Kerman	3,268	3,479	211	6%	67	11	411	+
Fars	5,343	5,541	198	4%	123	-172	567	-

Province	Expected deaths (regression)	Registered deaths	Excess deaths	%Excess deaths	SD Excess deaths	Excess deaths lower bound (Cl 95%)	Excess deaths upper bound (Cl 95%)
26 Provinces	78,672	95,914	17,242	22%	518	15,687	18,797